Position:
Professor
Division:
Neurology
Research Interests:

Epidemiological and Longitudinal Research Studies, Experimental Therapeutics and Clinical Trials on Alzheimer’s Disease, Research on Frontotemporal Dementia, Development of Biological Markers for Dementia.

Research Sumary:
Education:
DCS, McGill University, Arts
MDCM McGill University
FRCP(C) University of British Columbia
Recent Publications:
  • •Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. The potential for misclassification of Mild Cognitive Impairment: A study of memory scores on the Wechsler Memory Scale-III in Healthy Older Adults. Journal of the International Neuropsychological Society (JINS) 2008 (In press).
  • •Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, Schipper HM, Blair M, Kertesz A, and Chertkow H. The Diagnosis and Treatment of Dementia. Canadian Medical Association Journal 2008; 178(7): 825-836.
  • •Feldman HH, Maia LF, Mackenzie IRA, Forster BB, Martzke J, and Woolfenden A. Superficial siderosis: A diagnostic marker of Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Stroke 2008; 39(10): 2894-2897.
  • •Feldman HH, Maia LF, Mackenzie IRA, Forster BB, Martzke J, Woolfenden A. Superficial siderosis: A diagnostic marker of Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Stroke 2008 (In press).
  • •Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin J, Battisti W and Kavanagh S. Analyses of mortality risk in dementia patient treated with galantamine. Acta Neurologica Scandinavica 2008 [Epub ahead of print June 1, 2008].
  • •Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, and Kavanagh S. Treatment with galantamine and time to nursing home admission in Alzheimer disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2008 [Epub ahead of print November 4, 2008].
  • •Gauthier S, Dubois B, Feldman HH, and Scheltens P. Revised research criteria for Alzheimer’s disease. Lancet Neurology 2008; 7(8): 668-670.
  • •Hsiung G-YR and Feldman HH.  Pharmacological treatment in moderate-to-severe Alzheimer’s disease. Expert Opinion on Pharmacotherapy 2008 Oct.; 9(15): 2575-2582.
  • •Hsiung G-YR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, and Feldman HH. Transitions from CIND to Alzheimer’s Disease: An analysis of changes in functional abilities. Dementia & Geriatric Cognitive Disorders 2008; 25(6): 483-490.
  • •Hsiung G-YR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman HH. Transitions from CIND to Alzheimer’s Disease: An analysis of changes in functional abilities. Dementia & Geriatric Cognitive Disorders 2008 (In press).
  • •Jacova C, Peters KR, Wong E, Beattie BL, Foti D, Scheltens P, Li DKB, and Feldman HH. Cognitive Impairment No Impairment (CIND) – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup. Dementia & Geriatric Cognitive Disorders 2008 (In press).
  • •Jacova C, Peters KR, Wong E, Beattie BL, Foti D, Scheltens P, Li DKB, and Feldman HH. Cognitive Impairment No Impairment (CIND) – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup. Dementia & Geriatric Cognitive Disorders 2008; 25(3): 238-247.
  • •Jones RW, Kivipelto M, Feldman HH, Sparks L, Doody R, Waters D, Hey-Hadavi J, Breazna A, Schindler RJ, and Ramos H, on behalf of the LEADe Investigators. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and Baseline Characteristics. Alzheimer’s & Dementia 2008; 4(2): 145-153.
  • •Lane R, Feldman HH, Meyer J, Ferris SH, Nordberg A, Soininen H, Farlow MR, Sfikas N, Ballard C, Greig NH, Darreh-Shori T, Pirttilä T and He Y. Synergistic effect of APOE ?4 and BuChE-K on progression from MCI to Alzheimer’s disease. Pharmacogenetics and Genomics 2008 (In press).
  • •Lane R, Feldman HH, Meyer J, Ferris SH, Nordberg A, Soininen H, Farlow MR, Sfikas N, Ballard C, Greig NH, Darreh-Shori T, Pirttilä T, and He Y. Synergistic effect of APOE e4 and BuChE-K on progression from MCI to Alzheimer’s disease. Pharmacogenetics & Genomics 2008; 18: 289-298.
  • •Li H, Wetten S, L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes M, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung G-YR, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy English I, Matthews, P. Owen MJ, Plumpton M, Pryce Phillips W, Prinjha R, Gibson RA, Irizarry MC, Middleton LT, and Roses AD. Candidate Single Nucleotide Polymorphisms from a Genome-Wide Association St
  • •MaiaLi H, Wetten S,  L, Mackenzie IRA, and St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes M, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy., Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GYR, Johnson J Neurol Sci 2007;257(1-2):23-30., Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy English I, Matthews, P. Owen MJ, Plumpton M, Pryce Phillips W, Prinjha R, Gibson RA, Irizarry
  • •Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier SG, Loy-English I, Hsiung G-YR, Jacova C, Kertesz A, and Feldman HH. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry 2008; 16(2): 136-144.
  • •Peters KR, Rockwood K, King Moorhouse P, Song X, Macknight C, Black SE, Hogan DB, Gauthier SG, Loy-English I, Hisung G-Y R, Jacova C, Kertesz A, Montgomery P, Black S, Hogan DB, Guzman A, Bouchard R, and Feldman HH. Disease progression in vascular cognitive impairment: Cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. J Neurol Sci. 2007; 252: 106-112.Neuropsychiatric symptom clusters and functional disability in
  • •Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, Wszolek ZK, Uitti RJ, Feldman HH, Hutton ML, Mackenzie IR, Graff-Radford NR and Dickson DW.  Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.  Human Molecular Genetics 2008; 17(23): 3631-3642.
  • •Winblad B, Gauthier S, Scinto L, Feldman HH, Wilcock GK, Truyen L, Wang D, Nye JS, Brashear HR, and the GAL-INT-11/18 Study Group. Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment. Neurology 2008 (In press).
  • •Winblad B, Gauthier S, Scinto L, Feldman HH, Wilcock GK, Truyen L, Wang D, Nye JS, Brashear HR, and the GAL-INT-11/18 Study Group. Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment. Neurology 2008; 70(22): 20204-2035.
  • •Brooks BL, Iverson GL, Holdnack JA, and Feldman HH. The potential for misclassification of Mild Cognitive Impairment: A study of memory scores on the Wechsler Memory Scale-III in Healthy Older Adults. Journal of the International Neuropsychological Society (JINS) 2008 (In press).
  • •Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, Schipper HM, Blair M, Kertesz A, and Chertkow H. The Diagnosis and Treatment of Dementia. Canadian Medical Association Journal 2008; 178(7): 825-836.
  • •Feldman HH, Maia LF, Mackenzie IRA, Forster BB, Martzke J, and Woolfenden A. Superficial siderosis: A diagnostic marker of Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Stroke 2008; 39(10): 2894-2897.
  • •Feldman HH, Maia LF, Mackenzie IRA, Forster BB, Martzke J, Woolfenden A. Superficial siderosis: A diagnostic marker of Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Stroke 2008 (In press).
  • •Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin J, Battisti W and Kavanagh S. Analyses of mortality risk in dementia patient treated with galantamine. Acta Neurologica Scandinavica 2008 [Epub ahead of print June 1, 2008].
  • •Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, and Kavanagh S. Treatment with galantamine and time to nursing home admission in Alzheimer disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2008 [Epub ahead of print November 4, 2008].
  • •Gauthier S, Dubois B, Feldman HH, and Scheltens P. Revised research criteria for Alzheimer’s disease. Lancet Neurology 2008; 7(8): 668-670.
  • •Hsiung G-YR and Feldman HH.  Pharmacological treatment in moderate-to-severe Alzheimer’s disease. Expert Opinion on Pharmacotherapy 2008 Oct.; 9(15): 2575-2582.
  • •Hsiung G-YR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, and Feldman HH. Transitions from CIND to Alzheimer’s Disease: An analysis of changes in functional abilities. Dementia & Geriatric Cognitive Disorders 2008; 25(6): 483-490.
  • •Hsiung G-YR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman HH. Transitions from CIND to Alzheimer’s Disease: An analysis of changes in functional abilities. Dementia & Geriatric Cognitive Disorders 2008 (In press).
  • •Jacova C, Peters KR, Wong E, Beattie BL, Foti D, Scheltens P, Li DKB, and Feldman HH. Cognitive Impairment No Impairment (CIND) – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup. Dementia & Geriatric Cognitive Disorders 2008 (In press).
  • •Jacova C, Peters KR, Wong E, Beattie BL, Foti D, Scheltens P, Li DKB, and Feldman HH. Cognitive Impairment No Impairment (CIND) – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup. Dementia & Geriatric Cognitive Disorders 2008; 25(3): 238-247.
  • •Jones RW, Kivipelto M, Feldman HH, Sparks L, Doody R, Waters D, Hey-Hadavi J, Breazna A, Schindler RJ, and Ramos H, on behalf of the LEADe Investigators. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and Baseline Characteristics. Alzheimer’s & Dementia 2008; 4(2): 145-153.
  • •Lane R, Feldman HH, Meyer J, Ferris SH, Nordberg A, Soininen H, Farlow MR, Sfikas N, Ballard C, Greig NH, Darreh-Shori T, Pirttilä T and He Y. Synergistic effect of APOE ?4 and BuChE-K on progression from MCI to Alzheimer’s disease. Pharmacogenetics and Genomics 2008 (In press).
  • •Lane R, Feldman HH, Meyer J, Ferris SH, Nordberg A, Soininen H, Farlow MR, Sfikas N, Ballard C, Greig NH, Darreh-Shori T, Pirttilä T, and He Y. Synergistic effect of APOE e4 and BuChE-K on progression from MCI to Alzheimer’s disease. Pharmacogenetics & Genomics 2008; 18: 289-298.
  • •Li H, Wetten S, L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes M, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung G-YR, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy English I, Matthews, P. Owen MJ, Plumpton M, Pryce Phillips W, Prinjha R, Gibson RA, Irizarry MC, Middleton LT, and Roses AD. Candidate Single Nucleotide Polymorphisms from a Genome-Wide Association St
  • •MaiaLi H, Wetten S,  L, Mackenzie IRA, and St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes M, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy., Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GYR, Johnson J Neurol Sci 2007;257(1-2):23-30., Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy English I, Matthews, P. Owen MJ, Plumpton M, Pryce Phillips W, Prinjha R, Gibson RA, Irizarry
  • •Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier SG, Loy-English I, Hsiung G-YR, Jacova C, Kertesz A, and Feldman HH. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry 2008; 16(2): 136-144.
  • •Peters KR, Rockwood K, King Moorhouse P, Song X, Macknight C, Black SE, Hogan DB, Gauthier SG, Loy-English I, Hisung G-Y R, Jacova C, Kertesz A, Montgomery P, Black S, Hogan DB, Guzman A, Bouchard R, and Feldman HH. Disease progression in vascular cognitive impairment: Cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study. J Neurol Sci. 2007; 252: 106-112.Neuropsychiatric symptom clusters and functional disability in
  • •Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, Wszolek ZK, Uitti RJ, Feldman HH, Hutton ML, Mackenzie IR, Graff-Radford NR and Dickson DW.  Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.  Human Molecular Genetics 2008; 17(23): 3631-3642.
  • •Winblad B, Gauthier S, Scinto L, Feldman HH, Wilcock GK, Truyen L, Wang D, Nye JS, Brashear HR, and the GAL-INT-11/18 Study Group. Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment. Neurology 2008 (In press).
  • •Winblad B, Gauthier S, Scinto L, Feldman HH, Wilcock GK, Truyen L, Wang D, Nye JS, Brashear HR, and the GAL-INT-11/18 Study Group. Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment. Neurology 2008; 70(22): 20204-2035.
  • •Brooks BL, Iverson GL, Feldman, HH, and Holdnack JA. Minimizing misdiagnosis: Psychometric criteria for possible or probable memory impairment. Dementia & Geriatric Cognitive Disorders 2009; 27(5): 439-450.
  • •Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman, HH, Hsiung G-Y, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, St. George-Hyslop P, Wherrett J, and Monsch AU. An exploration of cognitive subgroups in Alzheimer’s Disease. Journal of the International Neuropsychological Society 2009 Dec4: 1-11 [epub ahead of print].
  • •Feldman, HH and Jacova C. Predicting treatment response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come? Nature Clinical Practice Neurology 2009; 5(3):128-129.
  • •Feldman, HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin J, Battisti W and Kavanagh S. Analyses of mortality risk in dementia patients treated with galantamine. Acta Neurologica Scandinavica 2009; 119(1): 22-31.
  • •Feldman, HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, and Kavanagh S. Treatment with galantamine and time to nursing home admission in Alzheimer disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2009; 24(5): 479-488.
  • •Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, and Feldman, HH.  Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender Medicine 2009; 6(2): 345-355.
  • •Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman, HH, Zhang R, Albert K, and Schindler R.  Rates of Cognitive Change in Alzheimer’s Disease: Observations Across a Decade of Placebo Controlled Clinical Trials With Donepezil.  Alzheimer’s Disease & Associated Disorders 2009; 23(4): 357-364.
  • •Kandiah N and Feldman, HH. Therapeutic potential of statins in Alzheimer’s disease. Journal of the Neurological Sciences 2009; 283(1-2): 230-234.
  • •Lanctot KL, Hsiung G-YR, Feldman, HH, Masoud ST, Sham L, and Herrmann N.  Assessing the validity of deriving Clinical Dementia Rating (CDR) Global scores from independently-obtained Functional Rating Scale (FRS) scores in vascular dementia with and without Alzheimer’s disease. International Journal of Geriatric Psychiatry 2009; 24(10):1174-1176.
  • •Moorhouse P, Song X, Rockwood K, Black S, Kertesz A, Gauthier S, and Feldman, HH, on behalf of the Consortium to Investigate Vascular Impairment of Cognition. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. Journal of the Neurological Sciences [Epub ahead of print October 17, 2009] 2010 Jan 15; 288(1-2): 142-6.
  • •Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez OL, Cummings J, Xu Y, and Feldman, HH.  Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease. Dementia & Geriatric Cognitive Disorders 2009; 28(3): 244-251.
  • •Woodward M, Black S, Jacova C, Kertesz A, Mackenzie IR, Feldman, HH and the ACCORD Investigator Group. Differentiating the frontal variant of Alzheimer’s Disease. International Journal of Geriatric Psychiatry 2009 [Epub ahead of print October 12, 2009].
  • •Brooks BL, Iverson GL, Feldman, HH, and Holdnack JA. Minimizing misdiagnosis: Psychometric criteria for possible or probable memory impairment. Dementia & Geriatric Cognitive Disorders 2009; 27(5): 439-450.
  • •Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman, HH, Hsiung G-Y, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, St. George-Hyslop P, Wherrett J, and Monsch AU. An exploration of cognitive subgroups in Alzheimer’s Disease. Journal of the International Neuropsychological Society 2009 Dec4: 1-11 [epub ahead of print].
  • •Feldman, HH and Jacova C. Predicting treatment response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come? Nature Clinical Practice Neurology 2009; 5(3):128-129.
  • •Feldman, HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin J, Battisti W and Kavanagh S. Analyses of mortality risk in dementia patients treated with galantamine. Acta Neurologica Scandinavica 2009; 119(1): 22-31.
  • •Feldman, HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, and Kavanagh S. Treatment with galantamine and time to nursing home admission in Alzheimer disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2009; 24(5): 479-488.
  • •Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, and Feldman, HH.  Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender Medicine 2009; 6(2): 345-355.
  • •Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman, HH, Zhang R, Albert K, and Schindler R.  Rates of Cognitive Change in Alzheimer’s Disease: Observations Across a Decade of Placebo Controlled Clinical Trials With Donepezil.  Alzheimer’s Disease & Associated Disorders 2009; 23(4): 357-364.
  • •Kandiah N and Feldman, HH. Therapeutic potential of statins in Alzheimer’s disease. Journal of the Neurological Sciences 2009; 283(1-2): 230-234.
  • •Lanctot KL, Hsiung G-YR, Feldman, HH, Masoud ST, Sham L, and Herrmann N.  Assessing the validity of deriving Clinical Dementia Rating (CDR) Global scores from independently-obtained Functional Rating Scale (FRS) scores in vascular dementia with and without Alzheimer’s disease. International Journal of Geriatric Psychiatry 2009; 24(10):1174-1176.
  • •Moorhouse P, Song X, Rockwood K, Black S, Kertesz A, Gauthier S, and Feldman, HH, on behalf of the Consortium to Investigate Vascular Impairment of Cognition. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. Journal of the Neurological Sciences [Epub ahead of print October 17, 2009] 2010 Jan 15; 288(1-2): 142-6.
  • •Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez OL, Cummings J, Xu Y, and Feldman, HH.  Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease. Dementia & Geriatric Cognitive Disorders 2009; 28(3): 244-251.
  • •Woodward M, Black S, Jacova C, Kertesz A, Mackenzie IR, Feldman, HH and the ACCORD Investigator Group. Differentiating the frontal variant of Alzheimer’s Disease. International Journal of Geriatric Psychiatry 2009 [Epub ahead of print October 12, 2009].
  • •Boxer AL, Mackenzie IR, Boeve BF, Baker M, Seeley WW, Feldman H, Hsiung GY, Karydas A, Whitwell J, A, Wojtas A, Goldman J, Miller BL, Rademakers R. Clinical, Neuroimaging, and Neuropathological Features of a New Chromosome 9p-linked FTD-ALS family. Dementia & Geri Cog Disord 2010:30(suppl 1): 58 and J Neurol Neurosurg Psychia 2010 (Epub ahead of print).
  • •Butler R, Beattie BL, PuangThong U, Dwosh E, Guimond C, Feldman H, Hsiung GY, Rogaeva E, St. George-Hyslop P., Sadovinck AD.  A Novel PS1 gene mutation in a larger aboriginal Kindred. Can J Neurol Sci 2010:37(3);359-364.
  • •Dubois B, Feldman H, Jacova C, Cummings J, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox, NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Kenichi M, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s Disease: A new lexicon. Lancet Neurology 2010;9(11):1118-27.
  • •Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR, Leavitt BR. Progranulin expression in the developing and adult murine brain. J Comp Neurol. 2010 Oct 1;518(19):3931-47.
  • •Tawankanjanachot I, Jacova C, Hsiung GY, Lee HS, McCormick S, Dinelle K, Sossi V, Sengdy P, Bouchard-Kerr P, Stoessl J, Feldman H, Mackenzie IR. Anterior and subcortical glucose hypometabolic rate in presymptomatic progranulin carriers. Dementia & Geri Cog Disord 2010:30(suppl 1): 82.
  • •Woodward, M, Jacova, C, Black, S, Kertesz, A, Mackenzie, I., Feldman, H. Differentiating the frontal variant of Alzheimer Disease. International Journal of Geriatric Psychiatry 2010:25(7);732-8.
  • •Boxer AL, Mackenzie IR, Boeve BF, Baker M, Seeley WW, Feldman H, Hsiung GY, Karydas A, Whitwell J, A, Wojtas A, Goldman J, Miller BL, Rademakers R. Clinical, Neuroimaging, and Neuropathological Features of a New Chromosome 9p-linked FTD-ALS family. Dementia & Geri Cog Disord 2010:30(suppl 1): 58 and J Neurol Neurosurg Psychia 2010 (Epub ahead of print).
  • •Butler R, Beattie BL, PuangThong U, Dwosh E, Guimond C, Feldman H, Hsiung GY, Rogaeva E, St. George-Hyslop P., Sadovinck AD.  A Novel PS1 gene mutation in a larger aboriginal Kindred. Can J Neurol Sci 2010:37(3);359-364.
  • •Dubois B, Feldman H, Jacova C, Cummings J, DeKosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox, NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Kenichi M, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s Disease: A new lexicon. Lancet Neurology 2010;9(11):1118-27.
  • •Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR, Leavitt BR. Progranulin expression in the developing and adult murine brain. J Comp Neurol. 2010 Oct 1;518(19):3931-47.
  • •Tawankanjanachot I, Jacova C, Hsiung GY, Lee HS, McCormick S, Dinelle K, Sossi V, Sengdy P, Bouchard-Kerr P, Stoessl J, Feldman H, Mackenzie IR. Anterior and subcortical glucose hypometabolic rate in presymptomatic progranulin carriers. Dementia & Geri Cog Disord 2010:30(suppl 1): 82.
  • •Woodward, M, Jacova, C, Black, S, Kertesz, A, Mackenzie, I., Feldman, H. Differentiating the frontal variant of Alzheimer Disease. International Journal of Geriatric Psychiatry 2010:25(7);732-8.